BLOCK, DIRK,BRUNNER, HANSPETER,DIETERLE, THOMAS,WIENHUES-THELEN, URSULA-HENRIKE,ZAUGG, CHRISTIAN,ZIEGLER, ANDRE
申请号：
CA2920066
公开号：
CA2920066A1
申请日:
2014.08.26
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
